What is Acrocyanosis in an infant?

  1. Raynaud M: On local asphyxia and symmetrical gangrene of the extremities [1862]. New researches on the nature and treatment of local asphyxia of the extremities [1874]. trans Selected monographs. Edited by: Barlow T. 1988, London: New Sydenham Society

    Google Scholar 

  2. Allen EV, Brown GE: Raynaud's disease: a critical review of minimal requisites for diagnosis. Am J Med Sci. 1932, 183: 187-200. 10.1097/00000441-193202000-00004.

    Article  Google Scholar 

  3. Summers A: From white to blue to red: Raynaud's phenomenon. Emergency Nurse. 2005, 13: 18-20. 10.1016/j.aaen.2004.10.010.

    Article  PubMed  Google Scholar 

  4. Block JA, Sequeira W: Raynaud's phenomenon. Lancet. 2001, 357: 2042-2048. 10.1016/S0140-6736(00)05118-7.

    CAS  Article  PubMed  Google Scholar 

  5. Ho M, Belch JJ: Raynaud's phenomenon: state of the art 1998. Scandinavian Journal of Rheumatology. 1998, 27: 319-322. 10.1080/03009749850154311.

    CAS  Article  PubMed  Google Scholar 

  6. Wigley FM: Clinical practice. Raynaud's Phenomenon. New England Journal of Medicine. 2002, 347: 1001-1008. 10.1056/NEJMcp013013.

    Article  PubMed  Google Scholar 

  7. DiMaio AM, Singh J: The infant with cyanosis in the emergency room. Pediatric Clinics of North America. 2006, 39: 987-1006.

    Google Scholar 

  8. Charkoudian N: Skin blood flow in adult human thermoregulation: how it works, when it does not, and why. Mayo Clinic Proceedings. 2003, 78: 603-612. 10.4065/78.5.603.

    Article  PubMed  Google Scholar 

  9. Krieger I, Brough AJ: Raynaud's phenomenon in an infant. Journal of Pediatrics. 1972, 80: 145-151. 10.1016/S0022-3476(72)80474-8.

    CAS  Article  PubMed  Google Scholar 

  10. De Angelis R, Del Medico P, Blasetti P, Cervini C: Raynaud's phenomenon: clinical spectrum of 118 patients. Clinical Rheumatology. 2003, 22: 279-284. 10.1007/s10067-003-0726-1.

    Article  PubMed  Google Scholar 

  11. Nigrovic PA, Fuhlbrigge RC, Sundel RP: Raynaud's phenomenon in children: a retrospective review of 123 patients. Pediatrics. 2003, 111: 715-721. 10.1542/peds.111.4.715.

    Article  PubMed  Google Scholar 

  12. Sheldon WB, Lurie DP, Maricq HR, Kahaleh MB, DeLustro FA, Gibofsky A, LeRoy EC: Three siblings with scleroderma (systemic sclerosis) and two with Raynaud's phenomenon from a single kindred. Arthritis & Rheumatism. 1981, 24: 668-676. 10.1002/art.1780240507.

    CAS  Article  Google Scholar 

  13. Guntheroth WG, Morgan BC, Harbinson JA, Mullins GL: Raynaud's disease in children. Circulation. 1967, 36: 724-729.

    CAS  Article  PubMed  Google Scholar 

  14. Abuaf N, Laperche S, Carsique R, Meyer O, Deschamps A, Rajoely B, Johanet C, Homberg JC: Antimitochondrial antibodies in the antiphospholipid syndrome. Clinical Reviews in Allergy & Immunology. 1995, 13: 57-65. 10.1007/BF02772249.

    CAS  Article  Google Scholar 

  15. Monti G, Galli M, Invernizzi F, Pioltelli P, Saccardo F, Monteverde A, Pietrogrande M, Renoldi P, Bombardieri S, Bordin G: Cryoglobulinaemias: a multi-centre study of the early clinical and laboratory manifestations of primary and secondary disease. GISC. Italian Group for the Study of Cryoglobulinaemias. Qjm. 1995, 88: 115-126.

    CAS  PubMed  Google Scholar 

  16. Shero JH, Bordwell B, Rothfield NF, Earnshaw WC: High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients. Science. 4739, 231: 737-740.

    Article  Google Scholar 

  17. al-Awami M, Schillinger M, Maca T, Gschwandtner M, Bieglmayer C, Wagner O, Minar E: Homocysteine levels in patients with Raynaud's phenomenon. Vasa. 2002, 31: 87-90. 10.1024/0301-1526.31.2.87.

    CAS  Article  PubMed  Google Scholar 

  18. Cooke JP, Marshall JM: Mechanisms of Raynaud's disease. Vascular Medicine. 2005, 10: 293-307. 10.1191/1358863x05vm639ra.

    Article  PubMed  Google Scholar 

  19. Herrick AL, Illingworth K, Blann A, Hay CR, Hollis S, Jayson MI: Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Annals of the Rheumatic Diseases. 1996, 55: 122-127. 10.1136/ard.55.2.122.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  20. Pistorius MA, Planchon B, Schott JJ, Lemarec H: Heredity and genetic aspects of Raynaud's disease. Journal des Maladies Vasculaires. 2006, 31: 10-15.

    CAS  Article  PubMed  Google Scholar 

  21. Rychlik-Golema W, Mastej K, Adamiec R: The role of endothelin-1 and selected cytokines in the pathogenesis of Raynaud's phenomenon associated with systemic connective tissue diseases. International Angiology. 2006, 25: 221-227.

    CAS  PubMed  Google Scholar 

  22. Czupryniak A, Kaluzynska A, Nowicki M, Wiecek B, Bald E, Owczarek D: Raynaud's phenomenon and endothelial dysfunction in end-stage renal disease patients treated with hemodialysis. Kidney & Blood Pressure Research. 2005, 28: 27-31. 10.1159/000081059.

    Article  Google Scholar 

  23. Lazzerini PE, Capecchi PL, Bisogno S, Cozzalupi M, Rossi PC, Pasini FL: Homocysteine and Raynaud's phenomenon: a review. Autoimmunity Reviews. 2010, 9: 181-187. 10.1016/j.autrev.2009.08.004.

    CAS  Article  PubMed  Google Scholar 

  24. LeRoy EC, Medsger TA: Raynaud's phenomenon: a proposal for classification. Clinical & Experimental Rheumatology. 1992, 10: 485-488.

    CAS  Google Scholar 

  25. Harel L, Straussberg R, Rudich H, Cohen AH, Amir J: Raynaud's phenomenon as a manifestation of parvovirus B19 infection: case reports and review of parvovirus B19 rheumatic and vasculitic syndromes. Clinical Infectious Diseases. 2000, 30: 500-503. 10.1086/313712.

    CAS  Article  PubMed  Google Scholar 

  26. Toumbis-Ioannou E, Cohen PR: Chemotherapy-induced Raynaud's phenomenon. Cleveland Clinic Journal of Medicine. 1994, 61: 195-199.

    CAS  Article  PubMed  Google Scholar 

  27. Kruit WH, Eggermont AM, Stoter G: Interferon-alpha induced Raynaud's syndrome. Annals of Oncology. 2000, 11: 1501-1502. 10.1023/A:1026586629166.

    CAS  Article  PubMed  Google Scholar 

  28. Kallenberg CG: Raynaud's phenomenon as an early sign of connective tissue diseases. Vasa Supplementum. 1992, 34: 25-28.

    CAS  PubMed  Google Scholar 

  29. Sayre JW: Raynaud's disease presenting in a 5-month-old-male infant. Pediatrics. 1973, 52: 412-415.

    CAS  PubMed  Google Scholar 

  30. Cutolo M, Sulli A, Secchi ME, Paolino S, Pizzorni C: Nailfold capillaroscopy is useful for the diagnosis and follow-up of autoimmune rheumatic diseases. A future tool for the analysis of microvascular heart involvement?. Rheumatology. 2006, 45 (Suppl 4): iv43-46.

    PubMed  Google Scholar 

  31. Planchon B, Pistorius MA, Beurrier P, De Faucal P: Primary Raynaud's phenomenon. Age of onset and pathogenesis in a prospective study of 424 patients. Angiology. 1994, 45: 677-686. 10.1177/000331979404500802.

    CAS  Article  PubMed  Google Scholar 

  32. Meli M, Gitzelmann G, Koppensteiner R, Amann-Vesti BR: Predictive value of nailfold capillaroscopy in patients with Raynaud's phenomenon. Clinical Rheumatology. 2006, 25: 153-158. 10.1007/s10067-005-1146-1.

    Article  PubMed  Google Scholar 

  33. Allen E, Brown G: Raynaud's disease: A critical review of minimal requisites for diagnosis. Am J Med Sci. 1932, 183-187.

    Google Scholar 

  34. Herrick AL: Pathogenesis of Raynaud's phenomenon. Rheumatology. 2005, 44: 587-596. 10.1093/rheumatology/keh552.

    CAS  Article  PubMed  Google Scholar 

  35. Duffy CM, Laxer RM, Lee P, Ramsay C, Fritzler M, Silverman ED: Raynaud syndrome in childhood. Journal of Pediatrics. 1989, 114: 73-78. 10.1016/S0022-3476(89)80604-3.

    CAS  Article  PubMed  Google Scholar 

  36. Singsen BH, Kornreich HK, Koster-King K, Brink SJ, Bernstein BH, Hanson V, Tan EM: Mixed connective tissue disease in children. Arthritis & Rheumatism. 1977, 20: 355-360.

    CAS  Google Scholar 

  37. Walker ID: Thrombophilia in pregnancy. J Clin Pathol. 2000, 53 (8): 573-80. 10.1136/jcp.53.8.573.

    PubMed Central  CAS  Article  PubMed  Google Scholar 

  38. Calhoon MJ, Ross CN, Pounder E, Cassidy D, Manco-Johnson MJ, Goldenberg NA: High prevalence of thrombophilic traits in children with family history of thromboembolism. Journal of Pediatrics. 2010, 157: 485-489. 10.1016/j.jpeds.2010.03.031.

    Article  PubMed  Google Scholar 

  39. Carmel R, Green R, Rosenblatt DS, Watkins D: Update on cobalamin, folate, and homocysteine. Hematology. 2003

    Google Scholar 

  40. Virdis A, Iglarz M, Neves MF, Amiri F, Touyz RM, Rozen R, Schiffrin EL: Effect of hyperhomocystinemia and hypertension on endothelial function in methylenetetrahydrofolate reductase-deficient mice. Arteriosclerosis, Thrombosis & Vascular Biology. 2003, 23: 1352-1357. 10.1161/01.ATV.0000083297.47245.DA.

    CAS  Article  Google Scholar 

  41. Tawakol A, Forgione MA, Stuehlinger M, Alpert NM, Cooke JP, Loscalzo J, Fischman AJ, Creager MA, Gewirtz H: Homocysteine impairs coronary microvascular dilator function in humans. Journal of the American College of Cardiology. 2002, 40: 1051-1058. 10.1016/S0735-1097(02)02069-7.

    CAS  Article  PubMed  Google Scholar 

  42. Cheng T-T, Chiu C-K: Elevated homocysteine levels in patients with Raynaud's phenomenon secondary to systemic lupus erythematosus. Clinical Rheumatology. 2002, 21: 251-254. 10.1007/s10067-002-8291-6.

    Article  PubMed  Google Scholar 

  43. Kingma K, Wollersheim H, Thien T: Double-blind, placebo-controlled study of intravenous prostacyclin on hemodynamics in severe Raynaud's phenomenon: the acute vasodilatory effect is not sustained. Journal of Cardiovascular Pharmacology. 1995, 26: 388-393. 10.1097/00005344-199509000-00007.

    CAS  Article  PubMed  Google Scholar 

  44. Vinjar B, Stewart M: Oral vasodilators for primary Raynaud's phenomenon. Cochrane Database of Systematic Reviews. 2008, CD006687-

    Google Scholar 

  45. van der Meer J, Wouda AA, Kallenberg CG, Wesseling H: A double-blind controlled trial of low dose acetylsalicylic acid and dipyridamole in the treatment of Raynaud's phenomenon. Vasa - Supplementum. 1987, 18: 71-75.

    CAS  PubMed  Google Scholar 

  46. Denton CP, Howell K, Stratton RJ, Black CM: Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot study. Clinical & Experimental Rheumatology. 2000, 18: 499-502.

    CAS  Google Scholar 

  47. Ortensi A, Salsano F, Trinchi S, D'Orazi V, Pisarri S: Microsurgical distal sympathectomy in chronic vasospastic syndromes of the hand. International Surgery. 2005, 90: 88-92.

    PubMed  Google Scholar 

  48. Belch JJ, Ho M: Pharmacotherapy of Raynaud's phenomenon. Drugs. 1996, 52: 682-695. 10.2165/00003495-199652050-00006.

    CAS  Article  PubMed  Google Scholar 

  49. Schiopu E, Hsu VM, Impens AJ, Rothman JA, McCloskey DA, Wilson JE, Phillips K, Seibold JR: Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis. Journal of Rheumatology. 2009, 36: 2264-2268. 10.3899/jrheum.090270.

    CAS  Article  PubMed  Google Scholar 


Page 2

Type of acrocyanosis Causes
Unilateral acrocyanosis  
  Local trauma/digital injury
  Local infection: Paronechia
  Raynaud's phenomenon
  Thoracic outlet syndrome
  Carpel Tunnel syndrome
  Cervical tumors compressing neurovascular bundle*
e.g. Neuroblastoma, stellate ganglion tumor
  Thromboembolism of arteries of palmar arch
  Frostbite
  Reflex Sympathetic dystrophy
Bilateral acrocyanosis**  
  Benign acrocyanosis of infancy
  Frostbite
  Pernio
  Raynaud's phenomenon
  Reflex sympathetic dystrophy
  Hypoxemia**
  Congenital cyanotic heart disease**
  Methemoglobinemia**
  Purpura fulminans
  Pheochromocytoma

  1. *: Need to look for other signs of Horner's syndrome on the ipsilateral side of the face (ptosis, anhydrosis, miosis of pupil or unequal pupils, poor light reflex and enopthalmos);**: Need close clinical evaluation for presence of central cyanosis.